(A) Synthesis of the cisplatin prodrug containing an additional drug moiety, (B) physical entrapment of two drugs in a nanodelivery vehicle, (C) incorporation of a fixed ratio of the cisplatin prodrug and other agents into single polymer for spatiotemporal controlled release, and (D) polymeric nanoparticles with ability to deliver drugs such as cisplatin, chlorambucil, or aspirin to the mitochondria of cisplatin-resistant cancer cells.